Many experimental studies on spinal cord injuries (SCIs) support behavioral improvement after Schwann cell treatment. This study was conducted to evaluate safety issues 2 years after intramedullary Schwann cell transplantation in 33 consecutively selected patients with SCI.
Of 356 patients with SCIs who had completed at least 6 months of a conventional rehabilitation program and who were screened for the study criteria, 33 were enrolled. After giving their informed consent, they volunteered for participation. They underwent sural nerve harvesting and intramedullary injection of a processed Schwann cell solution. Outcome assessments included a general health questionnaire, neurological examination, and functional recordings in terms of American Spinal Injury Association (ASIA) and Functional Independence Measure scoring, which were documented by independent observers. There were 24 patients with thoracic and 9 with cervical injuries. Sixteen patients were categorized in ASIA Grade A, and the 17 remaining participants had ASIA Grade B.
There were no cases of deep infection, and the follow-up MR imaging studies obtained at 2 years did not reveal any deformity related to the procedure. There was no case of permanent neurological worsening or any infectious or viral complications. No new increment in syrinx size or abnormal tissue and/or tumor formation were observed on contrast-enhanced MR imaging studies performed 2 years after the treatment.
Preliminary results, especially in terms of safety, seem to be promising, paving the way for future cell therapy trials.
Abbreviations used in this paper: ASIA = American Spinal Injury Association; FAM = Functional Assessment Measure; FIM = Functional Independence Measure; SCI = spinal cord injury.
Address correspondence to: Hooshang Saberi, M.D., M.P.H., Department of Neurosurgery, Brain and Spinal Injuries Repair Research Center, Tehran University of Medical Sciences, Imam Khomeini Hospital, Keshavarz Boulevard, Tehran 14197, Iran. email: email@example.com (cc: firstname.lastname@example.org).
Please include this information when citing this paper: published online July 29, 2011; DOI: 10.3171/2011.6.SPINE10917.
BlightACurtADitunnoJFDobkinBEllawayPFawcettJ: Position statement on the sale of unproven cellular therapies for spinal cord injury: the international campaign for cures of spinal cord injury paralysis. Spinal Cord47:713–7142009
CalleraFdo NascimentoRX: Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: a preliminary safety study. Exp Hematol34:130–1312006
FarinALiuCYLangmoenIAApuzzoML: Biological restoration of central nervous system architecture and function: part 3-stem cell- and cell-based applications and realities in the biological management of central nervous system disorders: traumatic, vascular, and epilepsy disorders. Neurosurgery65:831–8592009
FawcettJWCurtASteevesJDColemanWPTuszynskiMHLammertseD: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord45:190–2052007
FouadKSchnellLBungeMBSchwabMELiebscherTPearseDD: Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci25:1169–11782005
FranssenEHde BreeFMVerhaagenJ: Olfactory ensheathing glia: their contribution to primary olfactory nervous system regeneration and their regenerative potential following transplantation into the injured spinal cord. Brain Res Rev56:236–2582007
HawrylukGWRowlandJKwonBKFehlingsMG: Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus25:5E142008
HuangHChenLWangHXiHGouCZhangJ: Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38-month follow-up with MRI. Zhonqquo Xiu Fu Chong Jian Wai Ke Za Zhi20:439–4432006
ItoYSugimotoYTomiokaMKaiNTanakaM: Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury? : a prospective study about neurological recovery and early complications. Spine (Phila Pa 1976)34:2121–21242009
IwashitaYFawcettJWCrangAJFranklinRJBlakemoreWF: Schwann cells transplanted into normal and X-irradiated adult white matter do not migrate extensively and show poor long-term survival. Exp Neurol164:292–3022000
KnollerNAuerbachGFulgaVZeligGAttiasJBakimerR: Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine3:173–1812005
KocsisJDLankfordKLSasakiMRadtkeC: Unique in vivo properties of olfactory ensheathing cells that may contribute to neural repair and protection following spinal cord injury. Neurosci Lett456:137–1422009
LakatosABarnettSCFranklinRJ: Olfactory ensheathing cells induce less host astrocyte response and chondroitin sulphate proteoglycan expression than Schwann cells following transplantation into adult CNS white matter. Exp Neurol184:237–2462003
OlsonHERooneyGEGrossLNesbittJJGalvinKEKnightA: Neural stem cell- and Schwann cell-loaded biodegradable polymer scaffolds support axonal regeneration in the transected spinal cord. Tissue Eng Part A15:1797–18052009
RasouliABhatiaNSuryadevaraSCahillKGuptaR: Transplantation of preconditioned schwann cells in peripheral nerve grafts after contusion in the adult spinal cord. Improvement of recovery in a rat model. J Bone Joint Surg Am88:2400–24102006
Ribeiro-ResendeVTPimentel-CoelhoPMMesentier-LouroLAMendezRMMello-SilvaJPCabral-da-SilvaMC: Trophic activity derived from bone marrow mononuclear cells increases peripheral nerve regeneration by acting on both neuronal and glial cell populations. Neuroscience159:540–5492009
RøslandGVSvendsenATorsvikASobalaEMcCormackEImmervollH: Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res69:5331–53392009
SaberiHMoshayediPAghayanHRArjmandBHosseiniSKEmami-RazaviSH: Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett443:46–502008
SaitoFNakataniTIwaseMMaedaYHirakawaAMuraoY: Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. J Trauma64:53–592008
SomeyaYKodaMDezawaMKadotaTHashimotoMKamadaT: Reduction of cystic cavity, promotion of axonal regeneration and sparing, and functional recovery with transplanted bone marrow stromal cell-derived Schwann cells after contusion injury to the adult rat spinal cord. Laboratory investigation. J Neurosurg Spine9:600–6102008
SteevesJDLammertseDCurtAFawcettJWTuszynskiMHDitunnoJF: Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord45:206–2212007
TakamiTOudegaMBatesMLWoodPMKleitmanNBungeMB: Schwann cell but not olfactory ensheathing glia transplants improve hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord. J Neurosci22:6670–66812002
TuszynskiMHSteevesJDFawcettJWLammertseDKalichmanMRaskC: Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord45:222–2312007
WeidnerNBleschAGrillRJTuszynskiMH: Nerve growth factor-hypersecreting Schwann cell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1. J Comp Neurol413:495–5061999